Tower Research Capital (TRC)’s Aspire Biopharma ASBP Stock Holding History

Tower Research Capital (TRC)’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.24K	Buy	72 +64	+800%	+$3.41K	﹤0.01%	4512
2025 Q4	$1.27K	Sell	8 -18	-69%	-$4.5K	﹤0.01%	4727
2025 Q3	$6.41K	Buy	+26	New	+$13K	﹤0.01%	4161
2023 Q4	–	Hold	0	–	-$87	–	6220
2023 Q3	–	Hold	0	–	–	–	5744
2023 Q2	–	Sell	-1	Closed	-$16K	–	6415
2023 Q1	$16K	Buy	+1	New	+$12.5K	﹤0.01%	3744
2022 Q4	–	Hold	0	–	–	–	5258
2022 Q3	–	Hold	0	–	–	–	5637
2022 Q2	–	Hold	0	–	–	–	5273

Other funds holding ASBP

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

VWM

Valley Wealth Managers Paramus, New Jersey $1.55B AUM 28.47% 1-Year Est. Return

Tower Research Capital (TRC)'s ASBP Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Aspire Biopharma (ASBP) stake by 800% in Q1 2026, buying an estimated $3.41K and bringing the position to 72 shares worth $2.24K. The position accounts for ﹤0.01% of the portfolio, ranked #4512.

Tower Research Capital (TRC) first reported a position in ASBP in Q1 2023 and has held it in 4 quarters since. The position peaked at $16K in Q1 2023. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

Tower Research Capital (TRC) held 72 shares of Aspire Biopharma worth $2.24K as of Q1 2026.
Tower Research Capital (TRC) bought 64 Aspire Biopharma shares in Q1 2026, an estimated $3.41K.
Aspire Biopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4512 holding.
Tower Research Capital (TRC) first reported a position in Aspire Biopharma in Q1 2023 and has held it in 4 quarters since.
Tower Research Capital (TRC)'s Aspire Biopharma position peaked at $16K in Q1 2023.
12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.